tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Chad Messer, 3 are a HOLD (1.97%), 148 are a BUY (97.37%), 1 are a SELL (0.66%).
Analyst Chad Messer, carries an average stock price target met ratio of 47.55% that have a potential upside of 48.07% achieved within 248 days. Previously, Chad Messer worked at NEEDHAM.
Chad Messer’s has documented 273 price targets and ratings displayed on 22 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on GMDA, Gamida Cell Ltd at 20-Apr-2023.
Analyst best performing recommendations are on ARQL (ARQULE).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 9/14/2016. The price target of $47 was fulfilled within 5 days with a profit of $14.55 (44.84%) receiving and performance score of 89.68.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$57
$21.78 (61.84%)
$55
2 months 12 days ago
(10-Dec-2024)
5/6 (83.33%)
$10.98 (23.86%)
84
Buy
$75
$39.78 (112.95%)
$53
2 months 13 days ago
(09-Dec-2024)
6/7 (85.71%)
$26.36 (54.19%)
477
Buy
$51
$15.78 (44.80%)
4 months 12 days ago
(10-Oct-2024)
1/1 (100%)
$9.18 (21.95%)
27
Hold
$56
$20.78 (59.00%)
$61
4 months 26 days ago
(27-Sep-2024)
10/13 (76.92%)
$10.39 (22.78%)
223
Hold
$46
$10.78 (30.61%)
$30
8 months 9 days ago
(13-Jun-2024)
4/4 (100%)
$-0.77 (-1.65%)
169
What Year was the first public recommendation made by Chad Messer?
